NFKB1 and breast cancer: This results in suppression of NF-κB signaling and consequent M2-like polarization of tumor-associated macrophages in breast cancer mouse models, highlighting the potential of miR-182 targeting in reprogramming TAMs and limiting breast cancer progression.304 Together, these results establish a compelling foundation for developing RNA-based therapeutics targeting PPRs to treat infectious diseases, metabolic syndromes, and malignancies.